CVRx (CVRX) Retained Earnings : $-499.57 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CVRx Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. CVRx's retained earnings for the quarter that ended in Mar. 2024 was $-499.57 Mil.

CVRx's quarterly retained earnings declined from Sep. 2023 ($-468.22 Mil) to Dec. 2023 ($-477.38 Mil) and declined from Dec. 2023 ($-477.38 Mil) to Mar. 2024 ($-499.57 Mil).

CVRx's annual retained earnings declined from Dec. 2021 ($-394.75 Mil) to Dec. 2022 ($-436.18 Mil) and declined from Dec. 2022 ($-436.18 Mil) to Dec. 2023 ($-477.38 Mil).

CVRx Retained Earnings Historical Data

The historical data trend for CVRx's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Retained Earnings Chart

CVRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-337.57

-351.68

-394.75

-436.18

-477.38

CVRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial													-447.56	-459.21	-468.22	-477.38	-499.57

CVRx Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

CVRx (NAS:CVRX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

CVRx (CVRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445

Website

https://www.cvrx.com

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Executives

Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro	officer: Chief Marketing Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes	director	2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain	director	C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer	officer: SVP, U.S. Sales	9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P	10 percent owner
Nea Partners 10 L P	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo	director	100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim	officer: Chief Financial Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall	officer: Chief Strategy Officer and Sec	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding	officer: VP of Reg. Affairs and QA	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle	officer: VP of Global Clinical Research	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared	director, officer: Chief Executive Officer	9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445